Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

BMC Cancer

Table 4 Logistic regression of factors potentially associated with positive SARS-CoV-2 serology

Factor	Univariate analysis		Multivariate analysis
Factor	Odds ratio (95% CI)	P	Odds ratio (95% CI)	P
Age (≥ 65 vs < 65 years)	0.688 (0.249–1.903)	0.471
Comorbidity (absent vs present)	1.323 (0.499–3.510)	0.574
Cancer type (other vs lung)	0.882 (0.245–3.172)	0.848
Disease extent (localized vs metastatic)	2.350 (0.883–6.254)	0.087
Recent morbid surgery (yes vs no)	0.622 (0.130–2.973)	0.552
Thoracic radiotherapy < 6 months ago (yes vs no)	3.588 (1.196–10.767)	0.023
SARS-CoV-2 RT-PCR:
not performed vs negative	0.334 (0.079–1.423)	0.138	0.422 (0.092–1.941)	0.268
positive vs negative	43.920 (10.697–180.3)	< 0.001	31.159 (6.029–161.04)	< 0.001
Thoracic CT scan:
not done vs normal	6.390 (1.561–26.154)	0.010	4.698 (0.906–24.362)	0.065
COVID-19 suspected vs normal	28.522 (7.076–114.97)	< 0.001	14.574 (2.858–74.313)	0.001
COVID-19 symptoms*: yes vs no	7.526 (2.761–20.509)	< 0.001	4.080 (1.074–15.502)	0.039
Treatment
Chemotherapy vs others	1.317 (0.359–4.840)	0.678
Chemotherapy + immunotherapy vs others	0.873 (0.086–8.869)	0.909
Immunotherapy vs others	0.178 (0.018–1.752)	0.139

Performance status could not be added to the model as no patient with Eastern Cooperative Oncology Group 2–3 tested positive. Recent thoracic radiotherapy was not retained by the backward stepwise selection in the multivariate modeling
* Fever, cough or anosmia
^α Targeted therapy or antibody drug conjugate, approved or as part of a clinical study
CI confidence interval, CT computed tomography, COVID-19: The viral pandemic coronavirus disease 2019, SARS-CoV-2 severe acute respiratory syndrome coronavirus-2; vs: versus

ISSN: 1471-2407